Central Trust Company’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.89M | Buy |
9,945
+1,115
| +13% | +$210K | 0.03% | 269 |
|
|
2026
Q1 | $1.74M | Buy |
8,830
+1,473
| +20% | +$284K | 0.03% | 271 |
|
|
2025
Q4 | $1.35M | Buy |
7,357
+1,424
| +24% | +$250K | 0.03% | 295 |
|
|
2025
Q3 | $910K | Buy |
5,933
+224
| +4% | +$33.9K | 0.02% | 349 |
|
|
2025
Q2 | $798K | Sell |
5,709
-1,286
| -18% | -$180K | 0.02% | 361 |
|
|
2025
Q1 | $1.03M | Sell |
6,995
-1,298
| -16% | -$188K | 0.03% | 317 |
|
|
2024
Q4 | $1.09M | Sell |
8,293
-800
| -9% | -$112K | 0.03% | 308 |
|
|
2024
Q3 | $1.42M | Buy |
9,093
+4,799
| +112% | +$775K | 0.03% | 286 |
|
|
2024
Q2 | $670K | Sell |
4,294
-125
| -3% | -$18.8K | 0.02% | 371 |
|
|
2024
Q1 | $599K | Sell |
4,419
-124
| -3% | -$16.4K | 0.01% | 397 |
|
|
2023
Q4 | $612K | Sell |
4,543
-245
| -5% | -$31.8K | 0.02% | 379 |
|
|
2023
Q3 | $648K | Buy |
4,788
+102
| +2% | +$13.9K | 0.02% | 367 |
|
|
2023
Q2 | $671K | Buy |
4,686
+485
| +12% | +$71.4K | 0.02% | 372 |
|
|
2023
Q1 | $583K | Buy |
4,201
+117
| +3% | +$15.7K | 0.02% | 385 |
|
|
2022
Q4 | $554K | Sell |
4,084
-1,494
| -27% | -$187K | 0.02% | 379 |
|
|
2022
Q3 | $611K | Buy |
5,578
+391
| +8% | +$49.6K | 0.02% | 345 |
|
|
2022
Q2 | $686K | Sell |
5,187
-168
| -3% | -$22K | 0.02% | 335 |
|
|
2022
Q1 | $710K | Sell |
5,355
-769
| -13% | -$92.2K | 0.02% | 359 |
|
|
2021
Q4 | $714K | Sell |
6,124
-51
| -0.8% | -$6K | 0.02% | 384 |
|
|
2021
Q3 | $742K | Sell |
6,175
-26
| -0.4% | -$3.03K | 0.03% | 365 |
|
|
2021
Q2 | $743K | Buy |
6,201
+5,021
| +426% | +$551K | 0.03% | 354 |
|
|
2021
Q1 | $118K | Sell |
1,180
-4,444
| -79% | -$447K | ﹤0.01% | 576 |
|
|
2020
Q4 | $563K | Sell |
5,624
-168
| -3% | -$17.8K | 0.02% | 351 |
|
|
2020
Q3 | $635K | Buy |
5,792
+2,098
| +57% | +$233K | 0.03% | 311 |
|
|
2020
Q2 | $391K | Buy |
3,694
+2,716
| +278% | +$281K | 0.02% | 358 |
|
|
2020
Q1 | $87K | Hold |
978
| – | – | 0.01% | 530 |
|
|
2019
Q4 | $98K | Buy |
978
+9
| +0.9% | +$847 | 0.01% | 570 |
|
|
2019
Q3 | $86K | Buy |
969
+400
| +70% | +$34.7K | ﹤0.01% | 569 |
|
|
2019
Q2 | $46K | Sell |
569
-400
| -41% | -$31.4K | ﹤0.01% | 661 |
|
|
2019
Q1 | $78K | Hold |
969
| – | – | ﹤0.01% | 565 |
|
|
2018
Q4 | $74K | Hold |
969
| – | – | ﹤0.01% | 569 |
|
|
2018
Q3 | $77K | Hold |
969
| – | – | ﹤0.01% | 613 |
|
|
2018
Q2 | $68K | Sell |
969
-165
| -15% | -$11.9K | ﹤0.01% | 614 |
|
|
2018
Q1 | $79K | Sell |
1,134
-262
| -19% | -$18.1K | 0.01% | 602 |
|
|
2017
Q4 | $97K | Buy |
1,396
+192
| +16% | +$12.9K | 0.01% | 589 |
|
|
2017
Q3 | $81K | Sell |
1,204
-476
| -28% | -$30.1K | 0.01% | 599 |
|
|
2017
Q2 | $114K | Sell |
1,680
-570
| -25% | -$37.2K | 0.01% | 535 |
|
|
2017
Q1 | $140K | Buy |
2,250
+46
| +2% | +$2.68K | 0.01% | 510 |
|
|
2016
Q4 | $120K | Buy |
2,204
+1,142
| +108% | +$64.8K | 0.01% | 536 |
|
|
2016
Q3 | $70K | Buy |
1,062
+474
| +81% | +$31K | 0.01% | 590 |
|
|
2016
Q2 | $36K | Hold |
588
| – | – | ﹤0.01% | 751 |
|
|
2016
Q1 | $33K | Buy |
588
+125
| +27% | +$7.51K | ﹤0.01% | 766 |
|
|
2015
Q4 | $31K | Sell |
463
-386
| -45% | -$25.3K | ﹤0.01% | 764 |
|
|
2015
Q3 | $54K | Hold |
849
| – | – | ﹤0.01% | 615 |
|
|
2015
Q2 | $54K | Sell |
849
-40
| -4% | -$2.74K | ﹤0.01% | 646 |
|
|
2015
Q1 | $61K | Hold |
889
| – | – | ﹤0.01% | 608 |
|
|
2014
Q4 | $63K | Buy |
889
+213
| +32% | +$15.3K | 0.01% | 605 |
|
|
2014
Q3 | $48K | Sell |
676
-50
| -7% | -$3.66K | ﹤0.01% | 669 |
|
|
2014
Q2 | $54K | Sell |
726
-267
| -27% | -$19.3K | ﹤0.01% | 653 |
|
|
2014
Q1 | $64K | Sell |
993
-290
| -23% | -$18.7K | 0.01% | 611 |
|
|
2013
Q4 | $76K | Buy |
1,283
+63
| +5% | +$3.42K | 0.01% | 572 |
|
|
2013
Q3 | $63K | Hold |
1,220
| – | – | 0.01% | 594 |
|
|
2013
Q2 | $58K | Buy |
+1,220
| New | +$62.1K | 0.01% | 567 |
|
Other funds holding AZN
EP
IA
Central Trust Company's AZN Position: Q2 2026 in Review
Central Trust Company increased its AstraZeneca (AZN) stake by 13% in Q2 2026, buying an estimated $210K and bringing the position to 9,945 shares worth $1.89M. The position accounts for 0.03% of the portfolio, ranked #269.
Central Trust Company first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Central Trust Company held 9,945 shares of AstraZeneca worth $1.89M as of Q2 2026.
- Central Trust Company bought 1,115 AstraZeneca shares in Q2 2026, an estimated $210K.
- AstraZeneca made up 0.03% of Central Trust Company's portfolio in Q2 2026, its #269 holding.
- Central Trust Company first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
- 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.